Is Hyaluronic Acid (HA) Monotherapy Becoming Obsolete in Aesthetic Medicine?

HA Monotherapy vs. Combination Strategies — A Clinical Review for Aesthetic Practitioners

Introduction

Hyaluronic acid (HA) fillers have been the undisputed gold standard of injectable aesthetics for more than two decades, prized for their predictability, immediate volumizing effect, and reversibility with hyaluronidase. But aesthetic medicine is shifting. A growing body of clinical experience and published evidence suggests that combining HA with bio-stimulatory, energy-based, and neuromodulatory technologies produces more durable, natural-looking, and structurally holistic results than HA alone. This post summarizes the key talking points from our infographic “The Great Debate,” corrects a few labeling issues found during proofreading, and adds an evidence-based clinical commentary for practitioners weighing monotherapy against combination protocols.

Infographic Summary

The Conventional View — HA Monotherapy (“Gold Standard”)

Time-tested and proven: Predictable results supported by decades of clinical use.
Reversibility: Can be dissolved with hyaluronidase, offering a built-in safety margin.
Immediate volumization: Restores volume and fills folds instantly, with visible results at the time of injection.
Minimal downtime: Well suited to patients seeking quick, low-recovery treatments.
Patient satisfaction: High satisfaction rates for specific, localized indications.

The Emerging Trend — Combination Strategies (“Synergy for Better Outcomes”)

Multi-layered approach: Targets bone remodeling, fat pad atrophy, and skin quality together, not just volume loss.
Regenerative medicine focus: Aims to stimulate the patient’s own collagen and elastin production rather than only filling space.
Durability and longevity: Combination protocols are associated with more extended results compared with HA alone.
Natural-looking results: Layering modalities helps avoid an “overfilled” appearance.
Holistic face rejuvenation: Addresses both the structural (bone/fat/muscle) and superficial (skin texture, tone) components of facial aging.

Modalities Referenced in the “Shifting Paradigm”

Bio-stimulators: g., poly-L-lactic acid (PLLA) and calcium hydroxylapatite (CaHA), which promote gradual, host-mediated collagen synthesis.
Neurotoxins: Botulinum toxin type A, used to modulate muscle activity and dynamic wrinkling.
Energy-based devices: Lasers and radiofrequency (RF) devices, used to improve skin quality, tightening, and texture.
Skin boosters: Low-viscosity HA formulations injected superficially to improve hydration and skin quality rather than volume.

Bottom-Line Messaging From the Infographic

Monotherapy: Still clinically relevant for specific, localized needs (e.g., isolated volume deficits, lip augmentation, quick-turnaround treatments).
Combination: Better suited to addressing aging as a global, multi-tissue process rather than a single-plane volume problem.
Clinical insight: The future of aesthetic medicine is personalized and multimodal, tailoring the modality mix to each patient’s anatomy, goals, and budget.

Clinical Insights

1. The evidence increasingly favors combination protocols for global facial aging

Facial aging is now understood as a multi-tissue process involving bone remodeling, fat pad descent and atrophy, muscle activity, and skin quality decline — not a single-plane loss of HA-replaceable volume. This is the clinical rationale behind “multi-layered” and “holistic” protocols that pair HA with bio-stimulators, neurotoxin, and energy-based devices, rather than relying on filler volume alone.

2. Combining HA with calcium hydroxylapatite (CaHA) has growing procedural support

A 2025 systematic review of combined and hybrid HA/CaHA treatments (sequential dual-product protocols as well as syringe-to-syringe hybrid mixing) found that both approaches were associated with high aesthetic effectiveness and high patient/investigator satisfaction across facial regions, with a favorable safety profile and only minor, self-resolving adverse events; a modest decline in effect was noted by six months, reinforcing the importance of maintenance planning.

A separate multicenter retrospective study of a premixed CaHA:HA formulation used for jawline contouring reported that essentially all patients showed measurable improvement on a validated jawline aesthetic scale at three months, with most patients maintaining a clinically meaningful improvement at twelve months — supporting the infographic’s “durability and longevity” claim for combination approaches over HA alone.

It is worth noting that a formal editorial response to that systematic review cautioned that sequential (two-visit) combination therapy and true syringe-to-syringe hybrid mixing are mechanistically distinct approaches, and that in-clinic hybrid mixing currently lacks standardized, validated, or regulator-approved protocols. Practitioners should be precise about which strategy — sequential layering vs. off-label hybrid mixing — they are offering patients, and should counsel accordingly.

3. Bio-stimulators work through a different biological mechanism than HA

Unlike HA, which physically fills space and binds water, PLLA and CaHA act as bio-stimulators: their microparticles trigger a controlled foreign-body/inflammatory response that recruits macrophages and activates fibroblasts, gradually inducing the patient’s own neocollagenesis. This mechanistic difference is why bio-stimulators tend to produce a slower onset but more durable, “regenerative” result — complementary to, rather than a replacement for, the immediate volumizing effect of HA.

4. Reversibility remains HA’s unique safety advantage

None of the combination modalities referenced (PLLA, CaHA, energy-based devices) share HA’s key safety feature: hyaluronidase reversibility. This is clinically relevant when sequencing combination treatments — many practitioners still recommend placing HA strategically (or last) in a combined treatment plan, or spacing it from bio-stimulators, so that any correction needed can still be achieved without disturbing non-reversible components.

5. Monotherapy is not obsolete — it is an indication-specific tool

The infographic’s own conclusion is well supported: HA monotherapy remains the right choice for discrete, localized concerns (isolated tear-trough or lip volume, quick pre-event touch-ups, patients wanting maximal reversibility) where speed, predictability, and the ability to dissolve the product outweigh the benefits of a multimodal plan.

6. Practical takeaway for clinics and patient counseling

Assess structurally, not just volumetrically: distinguish bone/fat-pad loss, skin laxity, dynamic wrinkling, and textural change before choosing a modality mix.
Sequence deliberately: when layering HA with bio-stimulators or energy-based devices, plan order and interval based on mechanism and downtime, and document off-label hybrid mixing consent where applicable.
Set expectations on timeline: bio-stimulators build results over weeks to months, whereas HA and neurotoxin effects are immediate — patients should understand this before treatment.
Reassess at 6 and 12 months: published data show a partial decline in effect by six months even with combination protocols, so maintenance visits should be scheduled proactively.

Conclusion

HA monotherapy is not becoming obsolete — it is becoming one tool among several in an increasingly individualized treatment toolkit. The strongest current evidence supports combining HA with bio-stimulators, neurotoxin, and energy-based devices to address facial aging as the multi-tissue process it actually is, while reserving HA monotherapy for discrete, localized, or reversibility-sensitive indications. As the infographic concludes, the future of aesthetic medicine is personalized and multimodal — and treatment planning should follow the patient’s anatomy and goals, not a single default modality.

References

Meçani R, Amiri M, Kadouch J, et al. Combined and Hybrid Treatments of Hyaluronic Acid (HA) and Calcium Hydroxylapatite (CaHA): A Systematic Review of Mechanisms of Action, Aesthetic Effectiveness, Satisfaction, and Safety Profile. Aesthetic Plast Surg. 2025. doi:10.1007/s00266-025-04904-x.
Kerson G, Schumacher A. Response to: Combined and Hybrid Treatments of Hyaluronic Acid (HA) and Calcium Hydroxylapatite (CaHA)… Aesthetic Plast Surg. 2025. doi:10.1007/s00266-025-05265-1.
Combining Calcium Hydroxylapatite and Hyaluronic Acid Fillers for Aesthetic Indications: Efficacy of an Innovative Hybrid Filler. PMC8831259.
Dual Functionalization of Hyaluronan Dermal Fillers with Vitamin B3: Efficient Combination of Bio-Stimulation Properties with Hydrogel System Resilience Enhancement. PMC11203111.
Aesthetic Rehabilitation of Patients with Central and Peripheral Facial Palsy with Injectables (BoNT-A, HA-Fillers and CaHA). PMC12786528.